According to PersistenceMarketResearch, the global Meningococcal Vaccines Market is slated to witness a CAGR of more than 9% between 2020 and 2030.
Meningococcal vaccines are bound to make inroads to growth due to increasing incidences of meningitis all across. As per the CDC (Centers for Disease Control), the world is subject to nearly 1.2 Mn cases of meningitis every single year. Along these lines, an initiative known as “Defeating Meningitis by 2030” was announced in May 2018 by Eastern Mediterranean and African regions at the World Health Assembly with the objective of strategizing roadmap for preventing meningitis through control activities and research.
Besides, the Meningitis Research Foundation has approved investment close to US $28 Mn with 161 research grants.
By geography, North America holds the largest market share. Europe stands second. This could be attributed to extensive investments herein. For instance – NACI (National Advisory Committee on Immunization), in Dec 2019, did publish scientific recommendation and information on MenB-fHBP (bivalent factor-H binding protein meningococcal serogroup B) vaccine (Trumenba).
Get Sample article of report: https://www.persistencemarketresearch.com/samples/3640
Coming to Europe, the Ministry of Health of Ireland, in May 2019, did approve menACWY vaccine to be made available to loads of adults and children alike. Further developments are expected with the European Centre for Disease Prevention and Control (ECDC) confirming more than 8.2 cases per 100,000 population in infants (those aged less than 1).
LATAM and MEA have also picked up pace since the year 2018 (due to the reasons mentioned above). The key market participants include Pfizer Inc., Novartis AG, Sanofi, Serum Institute of India Ltd., GlaxoSmithKline plc, and Merck & Co., Inc. On the developments’ front, Pifizer has tabled a new-fangled molecular entity called “PF-06886992” to treat Serogroups ABCWY